此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项关于研究药物PF-08634404单药治疗及联合治疗在患有肝癌(肝细胞癌)成年受试者中的研究,该癌症已进展至无法通过手术切除且可能已扩散至身体其他部位。

2026年10月6日 更新者:Pfizer

一项干预性开放标签1B/2期研究,旨在评估PF-08634404作为单药治疗和联合治疗在患有不可切除局部晚期或转移性肝细胞癌的成年参与者中的安全性、药代动力学及初步疗效

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

  • Be 18 years or older.
  • Have locally advanced or metastatic HCC.
  • Is not a candidate for complete surgical or loco-regional therapies.
  • Have not received any whole-body treatment for HCC.

Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

研究概览

研究类型

介入性

注册 (估计的)

138

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • 招聘中
        • Zhongshan Hospital,Fudan University
      • Taichung、台湾、407
        • 招聘中
        • Taichung Veterans General Hospital
      • Tainan、台湾、704
        • 招聘中
        • National Cheng Kung University Hospital
      • Taipei、台湾、10002
        • 招聘中
        • National Taiwan University Hospital
      • Taipei、台湾、112
        • 招聘中
        • Taipei Veterans General Hospital
      • Fukuoka、日本、811-1395
        • 招聘中
        • National Hospital Organization Kyushu Cancer Center
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、464-8681
        • 招聘中
        • Aichi Cancer Center
    • Chiba
      • Kashiwa、Chiba、日本、277-8577
        • 招聘中
        • National Cancer Center Hospital East
    • Osaka
      • Sakai、Osaka、日本、590-0197
        • 招聘中
        • Kindai University Hospital- Osaka Medical Campus
    • Tokyo
      • Chuo-ku、Tokyo、日本、104-0045
        • 招聘中
        • National Cancer Center Hospital
      • San Juan、波多黎各、00909
        • 招聘中
        • Pan American Center for Oncology Trials, LLC
    • United States of America
      • Dorado、United States of America、波多黎各、00646
        • 招聘中
        • Pan American Center for Oncology Trials, LLC - Dorado Office
      • Mayagüez、United States of America、波多黎各、00680
        • 招聘中
        • Pan American Center for Oncology Trials, LLC - Mayaguez Office
      • Ponce、United States of America、波多黎各、00730
        • 招聘中
        • Pan American Center for Oncology Trials, LLC - Ponce Office
    • California
      • Irvine、California、美国、92612
        • 招聘中
        • Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Irvine、California、美国、92612
        • 招聘中
        • UCI Health - Irvine Infusion Pharmacy ACC
      • Irvine、California、美国、92612
        • 招聘中
        • UCI Health - Irvine
      • Los Angeles、California、美国、90033
        • 招聘中
        • USC/Norris Comprehensive Cancer Center
      • Los Angeles、California、美国、90033
        • 招聘中
        • Keck Hospital of USC
      • Los Angeles、California、美国、90033
        • 招聘中
        • USC/Norris Comprehensive Cancer Center / Investigational Drug Services
      • Los Angeles、California、美国、90033
        • 招聘中
        • Los Angeles General Medical Center
      • Los Angeles、California、美国、90025
        • 招聘中
        • START Los Angeles, LLC
      • Los Angeles、California、美国、90067
        • 招聘中
        • LACN Century City
      • Orange、California、美国、92868
        • 招聘中
        • UC Irvine Health - Chao Family Comprehensive Cancer Center
      • Pasadena、California、美国、91105
        • 招聘中
        • Keck Medical Center of USC Pasadena
    • Florida
      • Land O' Lakes、Florida、美国、34638
        • 招聘中
        • Moffitt Cancer Center at Speros
      • Ruskin、Florida、美国、33570
        • 招聘中
        • Moffitt Cancer Center at SouthShore
      • Tampa、Florida、美国、33612
        • 招聘中
        • Moffitt Cancer Center - McKinley Campus
      • Tampa、Florida、美国、33612
        • 招聘中
        • Moffitt Cancer Center
      • Tampa、Florida、美国、33612
        • 招聘中
        • Moffitt McKinley Hospital
      • Tampa、Florida、美国、33607
        • 招聘中
        • Moffitt Cancer Center - International Plaza
      • Wesley Chapel、Florida、美国、33544
        • 招聘中
        • Moffitt Cancer Center at Wesley Chapel
    • Illinois
      • Shiloh、Illinois、美国、62269
        • 招聘中
        • Siteman Cancer Center - Shiloh
      • Shiloh、Illinois、美国、62269
        • 招聘中
        • Memorial Hospital
    • Minnesota
      • Coon Rapids、Minnesota、美国、55433
        • 招聘中
        • Allina Health Cancer Institute - Mercy Hospital
      • Minneapolis、Minnesota、美国、55407
        • 招聘中
        • Allina Health Cancer Institute - Abbott Northwestern Hospital
      • Saint Paul、Minnesota、美国、55102
        • 招聘中
        • Allina Health Cancer Institute - United Hospital
    • Missouri
      • City of Saint Peters、Missouri、美国、63376
        • 招聘中
        • Siteman Cancer Center - St. Peters
      • Creve Coeur、Missouri、美国、63141
        • 招聘中
        • Siteman Cancer Center - West County
      • Florissant、Missouri、美国、63031
        • 招聘中
        • Siteman Cancer Center - North County
      • Kansas City、Missouri、美国、64111
        • 招聘中
        • Saint Luke's Hospital of Kansas City
      • Kansas City、Missouri、美国、64111
        • 招聘中
        • Saint Luke's Cancer Institute
      • St Louis、Missouri、美国、63108
        • 招聘中
        • Siteman Cancer Center
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Washington University School of Medicine - Siteman Cancer Center
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Barnes-Jewish Hospital
      • St Louis、Missouri、美国、63129
        • 招聘中
        • Siteman Cancer Center - South County
    • Nevada
      • Reno、Nevada、美国、89502
        • 招聘中
        • Renown Regional Medical Center
      • Reno、Nevada、美国、89502
        • 招聘中
        • Renown Health Medical Oncology
      • Reno、Nevada、美国、89502
        • 招聘中
        • Renown Office of Clinical Research
    • North Carolina
      • Cary、North Carolina、美国、27518
        • 招聘中
        • Duke Cancer Center Cary
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke Cancer Center
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke University - Main Hospital and Clinics
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke Cancer Center - Investigational Chemotherapy Service
      • Raleigh、North Carolina、美国、27609
        • 招聘中
        • Duke Cancer Center Raleigh
    • Ohio
      • Cleveland、Ohio、美国、44106
        • 招聘中
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15212
        • 招聘中
        • AHN Allegheny General Hospital
      • Pittsburgh、Pennsylvania、美国、15212
        • 招聘中
        • AHN Cancer Institute at Allegheny General Hospital
    • Washington
      • Seattle、Washington、美国、98101
        • 招聘中
        • Virginia Mason Medical Center
      • Seattle、Washington、美国、98109
        • 招聘中
        • Fred Hutchinson Cancer Center
      • Seattle、Washington、美国、98195
        • 招聘中
        • University of Washington Medical Center- Montlake

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 18 years of age or older at screening.
  • Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
  • Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
  • At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
  • Adequate hepatic, liver, and renal function
  • No prior systemic therapy for HCC.
  • ECOG performance status 0 or 1
  • Child-Pugh Class A

Key Exclusion Criteria:

  • Moderate or severe ascites.
  • History of hepatic encephalopathy.
  • Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
  • Clinically significant risk of hemorrhage or fistula.
  • Participants with any history of another malignancy within 3 years.
  • History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
  • Clinically significant cardiovascular disease within 6 months prior to the first dose.
  • Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
  • History of severe bleeding tendency or coagulation dysfunction.
  • History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
  • Participants with acute, chronic or symptomatic infections.
  • Participants with history of immunodeficiency.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Phase 1b

Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab.

Solution for infusion

Solution for infusion

其他名称:
  • 远航
实验性的:Phase 2

Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab.

Solution for infusion

Solution for infusion

其他名称:
  • 远航

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Adverse Events
大体时间:Through end of study and up to approximately 24 months

Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Through end of study and up to approximately 24 months
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
大体时间:Through 90 days after the last dose of study intervention; Approximately 24 months

DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period.

Through 90 days after the last dose of study intervention; Approximately 24 months
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
大体时间:Approximately 24 months

ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator.

Approximately 24 months
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
大体时间:Approximately 24 months

The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2.

Approximately 24 months

次要结果测量

结果测量
措施说明
大体时间
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
大体时间:Approximately 24 months

ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator.

Approximately 24 months
Duration of Response (DOR) per RECIST 1.1 by investigator
大体时间:Approximately 24 months

DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 24 months
Progression Free Survival (PFS) per RECIST 1.1 by investigator
大体时间:Approximately 24 months

PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 24 months
Overall Survival (OS)
大体时间:Approximately 24 months

OS is defined as the time from the date of first dose to the date of death due to any cause.

Approximately 24 months
Number of Participants With Clinical Laboratory Abnormalities
大体时间:Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
Pharmacokinetics (PK): Serum concentrations of PF-08634404
大体时间:Up to 24 months

Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab.

Up to 24 months
Incidence of antidrug antibody against PF-08634404
大体时间:Up to 24 months

To evaluate immunogenicity of PF-08634404 in combination with ipilimumab.

Up to 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月1日

初级完成 (估计的)

2027年10月18日

研究完成 (估计的)

2028年10月17日

研究注册日期

首次提交

2025年11月7日

首先提交符合 QC 标准的

2025年11月7日

首次发布 (实际的)

2025年11月12日

研究记录更新

最后更新发布 (实际的)

2026年10月8日

上次提交的符合 QC 标准的更新

2026年10月6日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅